Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Inamura, Yuki Togashi, M. Okui, H. Ninomiya, M. Hiramatsu, Y. Satoh, S. Okumura, K. Nakagawa, T. Shimoji, T. Noda, Y. Ishikawa (2007)HOXB2 as a Novel Prognostic Indicator for Stage I Lung Adenocarcinomas
Journal of Thoracic Oncology, 2
H. Shigematsu, Li Lin, Takao Takahashi, M. Nomura, Makoto Suzuki, I. Wistuba, K. Fong, Hue Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Ziding Feng, J. Roth, J. Herz, J. Minna, A. Gazdar (2006)Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
Journal of the National Cancer Institute, 97 5
M. Soda, Y. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, H. Mano (2007)Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
W. Chan, Qing-Rong Liu, J. Borjigin, H. Busch, O. Rennert, L. Tease, P. Chan (1989)Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth.
Biochemistry, 28 3
M. Shiota, J. Fujimoto, T. Semba, H. Satoh, Tadashi Yamamoto, S. Mori (1994)Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3.
Oncogene, 9 6
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
H. Stein, H. Foss, H. Dürkop, T. Marafioti, G. Delsol, K. Pulford, S. Pileri, B. Falini (2000)CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
Blood, 96 12
K. Pulford, L. Lamant, S. Morris, L. Butler, K. Wood, D. Stroud, G. Delsol, D. Mason (1997)Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.
Blood, 89 4
(1999)General Rules for Clinical and Pathologic Record of Lung Cancer
L. Hernández, M. Pinyol, S. Hernández, S. Beà, K. Pulford, A. Rosenwald, L. Lamant, B. Falini, G. Ott, D. Mason, G. Delsol, E. Campo (1999)TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations.
Blood, 94 9
L. Lamant, N. Dastugue, K. Pulford, G. Delsol, B. Mariamé (1999)A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation.
Blood, 93 9
J. Duyster, Ren-Yuan Bai, S. Morris (2001)Translocations involving anaplastic lymphoma kinase (ALK)
T. Lynch, D. Bell, Raffaella Sordella, S. Gurubhagavatula, R. Okimoto, Brian Brannigan, Patricia Harris, Sara Haserlat, J. Supko, F. Haluska, D. Louis, D. Christiani, J. Settleman, D. Haber (2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
The New England journal of medicine, 350 21
Y. Ishikawa, R. Furuta, T. Miyoshi, Y. Satoh, S. Okumura, K. Nakagawa, E. Tsuchiya (2002)Loss of heterozygosity and the smoking index increase with decrease in differentiation of lung adenocarcinomas: etiologic implications.
Cancer letters, 187 1-2
M. Pollmann, R. Parwaresch, S. Adam‐Klages, M. Kruse, F. Buck, H. Heidebrecht (2006)Human EML4, a novel member of the EMAP family, is essential for microtubule formation.
Experimental cell research, 312 17
P. Paepe, M. Baens, H. Krieken, B. Verhasselt, M. Stul, A. Simons, B. Poppe, G. Laureys, P. Brons, P. Vandenberghe, F. Speleman, M. Praet, C. Wolf‐Peeters, P. Marynen, I. Wlodarska (2003)ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma.
Blood, 102 7
K. Inamura, Yuki Togashi, K. Nomura, H. Ninomiya, M. Hiramatsu, M. Okui, Y. Satoh, S. Okumura, K. Nakagawa, E. Tsuchiya, Y. Ishikawa (2007)Up-regulation of PTEN at the transcriptional level is an adverse prognostic factor in female lung adenocarcinomas.
Lung cancer, 57 2
K. Inamura, Yuki Togashi, K. Nomura, H. Ninomiya, M. Hiramatsu, Y. Satoh, S. Okumura, K. Nakagawa, Y. Ishikawa (2007)let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis.
Lung cancer, 58 3
Michael Jones, C. Virtanen, Daisuke Honjoh, T. Miyoshi, Y. Satoh, S. Okumura, K. Nakagawa, Hitoshi Nomura, Y. Ishikawa (2004)Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles
The Lancet, 363
B. Lawrence, A. Perez-Atayde, M. Hibbard, B. Rubin, P. Cin, J. Pinkus, G. Pinkus, S. Xiao, E. Yi, C. Fletcher, J. Fletcher, J. Fletcher (2000)TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.
The American journal of pathology, 157 2
J. Eudy, M. Ma-Edmonds, S. Yao, C. Talmadge, P. Kelley, M. Weston, W. Kimberling, J. Sumegi (1997)Isolation of a novel human homologue of the gene coding for echinoderm microtubule-associated protein (EMAP) from the Usher syndrome type 1a locus at 14q32.
Genomics, 43 1
K. Inamura, Takeshi Fujiwara, Y. Hoshida, T. Isagawa, Michael Jones, C. Virtanen, M. Shimane, Y. Satoh, S. Okumura, K. Nakagawa, E. Tsuchiya, S. Ishikawa, H. Aburatani, H. Nomura, Y. Ishikawa (2005)Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization
K. Inamura, T. Shimoji, H. Ninomiya, M. Hiramatsu, M. Okui, Y. Satoh, S. Okumura, K. Nakagawa, T. Noda, M. Fukayama, Y. Ishikawa (2007)A metastatic signature in entire lung adenocarcinomas irrespective of morphological heterogeneity.
Human pathology, 38 5
W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, Bhuvanesh Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, Doris Kupfer, R. Wilson, M. Kris, H. Varmus (2004)EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Proceedings of the National Academy of Sciences of the United States of America, 101 36
(2004)World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleural, Thymus and Heart
S. Morris, C. Naeve, P. Mathew, P. James, M. Kirstein, Xiaoli Cui, D. Witte (1997)ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)
S. Morris, M. Kirstein, M. Valentine, K. Dittmer, D. Shapiro, D. Saltman, A. Look (1994)Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
Science, 267 5196
C. Virtanen, Y. Ishikawa, Daisuke Honjoh, M. Kimura, M. Shimane, T. Miyoshi, H. Nomura, Michael Jones (2002)Integrated classification of lung tumors and cell lines by expression profiling
Proceedings of the National Academy of Sciences of the United States of America, 99
ORIGINAL ARTICLE EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers Kentaro Inamura, MD, PhD,* Kengo Takeuchi, MD, PhD,* Yuki Togashi, MPharm,* Kimie Nomura,* Hironori Ninomiya, MD,* Michiyo Okui, PhD,* Yukitoshi Satoh, MD, PhD,*† Sakae Okumura, MD,† Ken Nakagawa, MD,† Manabu Soda, MD, PhD,‡ Young Lim Choi, MD, PhD,‡ Toshiro Niki, MD, PhD,§ Hiroyuki Mano, MD, PhD,‡ and Yuichi Ishikawa, MD, PhD* Keywords: Lung cancer, EML4-ALK, RT-PCR, Immunohisto- Introduction: Very recently, we have found a novel fusion product chemistry, Histology. between the echinoderm microtubule-associated protein-like4 (J Thorac Oncol. 2008;3: 13–17) (EML4) and the anaplastic lymphoma kinase (ALK) in non-small cell lung cancers (NSCLCs). Tumors featuring EML4-ALK fusion constitute one subtype of NSCLC that might be highly sensitive to ung cancer is the leading cause of cancer death in men and ALK inhibitors. Herein, we present results of a ﬁrst large scale study Lwomen worldwide. Identiﬁcation of activating mutations of EML4-ALK fusion in lung cancers. of the epidermal growth factor receptor (EGFR) is one of the Methods: Using reverse transcription-polymerase chain reaction for most intriguing recent discoveries in the ﬁeld of lung cancer EML4-ALK fusion mRNA, we investigated 149 lung adenocarci- 1,2 research. EGFR mutations are
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Jan 1, 2008
Access the full text.
Sign up today, get DeepDyve free for 14 days.